{"context":{"query":">>hgnc>>gencc","source_dataset":"hgnc","target_dataset":"gencc"},"stats":{"queried":1,"total":6,"mapped":1},"pagination":{"has_next":false},"schema":"id|gene_symbol|disease_title|classification_title|moi_title|submitter_title","mappings":[{"input":"HGNC:1787","source":"HGNC:1787|cyclin dependent kinase inhibitor 2A","targets":["GENCC_000101-HGNC_1787-OMIM_155755-HP_0000006-GENCC_100004|CDKN2A|melanoma and neural system tumor syndrome|Limited|Autosomal dominant|Ambry Genetics","GENCC_000101-HGNC_1787-OMIM_606719-HP_0000006-GENCC_100001|CDKN2A|melanoma-pancreatic cancer syndrome|Definitive|Autosomal dominant|Ambry Genetics","GENCC_000104-HGNC_1787-OMIM_606719-HP_0000006-GENCC_100002|CDKN2A|melanoma-pancreatic cancer syndrome|Strong|Autosomal dominant|Genomics England PanelApp","GENCC_000106-HGNC_1787-OMIM_606719-HP_0000006-GENCC_100002|CDKN2A|melanoma-pancreatic cancer syndrome|Strong|Autosomal dominant|Labcorp Genetics (formerly Invitae)","GENCC_000110-HGNC_1787-ORPHANET_404560-HP_0000006-GENCC_100009|CDKN2A|familial atypical multiple mole melanoma syndrome|Supportive|Autosomal dominant|Orphanet","GENCC_000112-HGNC_1787-OMIM_155601-HP_0000006-GENCC_100001|CDKN2A|melanoma, cutaneous malignant, susceptibility to, 2|Definitive|Autosomal dominant|G2P"]}]}